Despite the positive results, there are drawbacks, such as increased toxicity levels, surviving tumor cells adapting to therapeutic agents, combined therapies negating each other, and therapeutic targets still being studied and considering that these LIF targeting inhibitors or antibodies could be utilized in glioblastoma [52,111,112,113,114,115,116]. Here, LIF is linked to glioblastoma.